Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Omega Funds

Investor type Venture Capital
Founders Otello Stampacchia

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 124
Average round size
info
The average size of a deal this fund participated in
$62M
Portfolio companies 91
Rounds per year 6.89
Lead investments 21
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.27
Exits 48
Key employees 3
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Pharmaceutical
  • Medical
Summary

The company was established in North America in United States. The leading representative office of defined VC is situated in the Boston.

Deals in the range of 10 - 50 millions dollars are the general things for fund. The increased amount of exits for fund were in 2019. The fund is generally included in 2-6 deals every year. Comparing to the other companies, this Omega Funds performs on 7 percentage points more the average number of lead investments. Speaking about the real fund results, this VC is 0 percentage points less often commits exit comparing to other organizations. The high activity for fund was in 2017.

Besides them, we counted 3 critical employees of this fund in our database.

Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Intarcia Therapeutics, Gossamer Bio, Beam Therapeutics. The fund has no exact preference in some founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the most popular fund investment industries, there are Biotechnology, Medical.

The standard case for the fund is to invest in rounds with 6-7 partakers. Despite the Omega Funds, startups are often financed by Polaris Partners, Flagship Pioneering, New Enterprise Associates. The meaningful sponsors for the fund in investment in the same round are New Enterprise Associates, Abingworth, The Baupost Group. In the next rounds fund is usually obtained by Polaris Partners, Atlas Venture, The Baupost Group.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Omega Funds:
Typical Co-investors
Omega Funds is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Omega Funds:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
3W Partners Missouri, Saint Louis, United States
Aesop Capital California, San Francisco, United States
Assets New Ventures -
Brio Capital Management New York, New York, United States
JNS HOLDINGS Japan, Tokyo
MAN Truck & Bus Bayern, Germany, Munich
Mintian Capital -
Pentech Ventures City of Edinburgh, Scotland, United Kingdom
Platform Investment Partners Gauteng, Johannesburg, South Africa
SAINT-CARE HOLDINGS Japan, Tokyo
Shenshang Xingye Fund -
Shenzhen Qianhai Huaye Yuan Touzi China, Guangdong, Shenzhen
TCG Crossover California, Palo Alto, United States
TrustCapital India, Maharashtra, Mumbai
Ufi Ventures England, London, United Kingdom
Yanlingxian Qianqian Shangmao China, Henan, Henan

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Photys Therapeutics

Biotechnology
$75M08 Sep 2022 Cambridge, Massachusetts, United States

eTheRNA immunotherapies

Biotechnology
Medical Device
Therapeutics
$46M23 Aug 2022 Belgium, Belgium

Upstream Bio

Health Care
Pharmaceutical
$200M02 Jun 2022 Waltham, Massachusetts, United States

CDR-Life AG

Biotechnology
$76M13 Apr 2022 Schlieren, Zurich, Switzerland

Aerium Therapeutics

Biopharma
Health Care
Medical
Pharmaceutical
Therapeutics
22 Mar 2022 Boston, Massachusetts, United States

Endeavor BioMedicines

Biotechnology
$101M07 Feb 2022 California, United States

Chroma Medicine

Biotechnology
Medical
Therapeutics
$125M17 Nov 2021 Cambridge, Massachusetts, United States

Rectify Pharmaceuticals

Biotechnology
Life Science
Therapeutics
$100M14 Oct 2021 Cambridge, Massachusetts, United States

CinCor Pharma

Pharmaceutical
Therapeutics
$143M12 Oct 2021 Cincinnati, Ohio, United States
News
Anjarium Biosciences Raises $61M in Series A Financing

– Anjarium Biosciences AG is a Schliren, Zurich-based biotech company focused on creating and delivering a new class of non-viral gene therapies.
– Series A funding closed at $61m.
– The round was co-led by Abingworth and Gimv, with participation from Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company).
– The new investment will be used to advance the company’s pipeline programs towards clinical development.

Anjarium Biosciences Raises $61M in Series A Financing

– Anjarium Biosciences AG is a Schliren, Zurich-based biotech company focused on creating and delivering a new class of non-viral gene therapies.
– Series A funding closed at $61m.
– The round was co-led by Abingworth and Gimv, with participation from Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company).
– The new investment will be used to advance the company’s pipeline programs towards clinical development.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Omega Funds?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: